| Schedule of financial information by reporting segment |
| | | | | | | | | Three Months Ended | | | March 31, | | | 2026 | | 2025 | | | | (in thousands) | Net revenues: | | $ | 171,171 | | $ | 170,528 | Less: | | | | | | | Payroll expense | | | 50,618 | | | 49,310 | Materials and supplies | | | 12,741 | | | 10,479 | Clinical trials expense | | | 1,552 | | | 948 | Depreciation and amortization expense | | | 14,348 | | | 13,609 | Stock-based compensation expense | | | 9,274 | | | 8,393 | Consulting and outside services expense | | | 10,362 | | | 9,585 | Advertising and promotional expense | | | 3,060 | | | 3,889 | Other segment items(1) | | | 55,011 | | | 39,256 | Interest income | | | (2,400) | | | (2,089) | Interest expense | | | 6,553 | | | 6,286 | Income tax provision | | | 3,632 | | | 5,577 | Net income | | $ | 6,420 | | $ | 25,285 |
| (1) | Other segment items primarily include maintenance and repairs expense, travel expense, professional services expense, legal expense, rent expense, product costs, certain overhead expenses, manufacturing cost absorption and variances, inventory provisions, miscellaneous expenses, and foreign currency exchange gains and losses. |
|
| Schedule of net revenues in the finished pharmaceutical products segment |
| | | | | | | | | Three Months Ended | | | March 31, | | | 2026 | | 2025 | | | | (in thousands) | Net revenues: | | | | | | | BAQSIMI® | | $ | 32,434 | | $ | 38,355 | Primatene MIST® | | | 29,763 | | | 29,051 | Epinephrine | | | 19,213 | | | 18,587 | Lidocaine | | | 13,460 | | | 13,644 | Glucagon | | | 9,170 | | | 20,843 | Other products | | | 67,131 | | | 50,048 | Total net revenues | | $ | 171,171 | | $ | 170,528 |
|
| Schedule of net revenues and carrying values of long-lived assets by geographic region |
| | | | | | | | | | | | | | | Net Revenues | | Long-Lived Assets | | | Three Months Ended | | | | | | | | | March 31, | | March 31, | | December 31, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | (in thousands) | United States | | $ | 159,040 | | $ | 162,590 | | $ | 235,034 | | $ | 206,697 | China | | | 2,482 | | | 81 | | | 108,557 | | | 110,055 | France | | | 9,649 | | | 7,857 | | | 35,321 | | | 36,967 | Total | | $ | 171,171 | | $ | 170,528 | | $ | 378,912 | | $ | 353,719 |
|